NCT06673498View on ClinicalTrials.gov

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 10, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Thrombocytopenia
Interventions
DRUG

Lusutrombopag combined with recombinant human thrombopoietin

After eligibility is confirmed, patients will begin treatment with Lusutrombopag +recombinant human thrombopoietin on Day 1, and study treatment will continue for 7 days

Trial Locations (2)

230000

RECRUITING

Anhui province hospital, Hefei

236015

RECRUITING

No.2 People's Hospital of Fuyang city, Fuyang

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV